Welcome to our dedicated page for AIIDA news (Ticker: AIIDA), a resource for investors and traders seeking the latest updates and insights on AIIDA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AIIDA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AIIDA's position in the market.
Almonty Industries (NASDAQ:ALM) has announced the pricing of its oversubscribed US$90 million public offering concurrent with its Nasdaq listing. The company is offering 20 million common shares at US$4.50 per share, with an additional 30-day over-allotment option for 3 million shares.
Trading on Nasdaq is set to commence on July 14, 2025, under the ticker "ALM". The offering, led by Oppenheimer & Co. and Cantor as Joint Bookrunners, is expected to close around July 15, 2025. The proceeds will primarily fund the development of Almonty's tungsten oxide facility and working capital needs.
The company will maintain its listings on the TSX (AII), ASX (AiiDA), and Frankfurt Exchange, while its OTCQX trading was suspended on July 11, 2025.
